David Henry's JCSO Podcast

David Henry's JCSO podcast, March-April 2018


 

In his bimonthly podcast, Dr David Henry, the JCSO Editor-in-Chief, discusses the approval of the biosimilars, bevacizumab-awwb and trastuzumab-dkst, and new therapies for virally associated cancers. Also in the line-up are an interview with Dr Daniel Haller on the latest advances in treating gastrointestinal cancers, and an article on hands-on advice on integrating survivorship care planning in a radiation oncology workflow. Research topics incude how to improve communication between oncology care providers and patient caregivers during hospice; the impact of patient education on enrollment in clinical trials; and organizational barriers to optimal lung cancer care in the community setting. A series of Case Reports that highlight some of the clincial challenges in treating patients with cancer round out the issue.

Listen to the podcast below

Recommended Reading

Preprint publishing challenges the status quo in medicine
MDedge Hematology and Oncology
MDedge Daily News: Why low-calorie sucralose may fuel weight gain
MDedge Hematology and Oncology
Checkpoint inhibition less toxic than antiangiogenic therapy in NSCLC
MDedge Hematology and Oncology
Most patients off transfusions after gene therapy for thalassemia
MDedge Hematology and Oncology
Think about breast cancer surveillance for transgender patients
MDedge Hematology and Oncology
Warfarin dose capping avoided supratherapeutic INRs in hospitalized elderly
MDedge Hematology and Oncology
Single screening for Lynch syndrome beats sequential tests in CRC
MDedge Hematology and Oncology
Protocol helped identify hospitalized children at risk for VTE
MDedge Hematology and Oncology
Disease, genetics contribute to neurocognitive decline in ALL
MDedge Hematology and Oncology
Drug approved to treat all adults with iron deficiency
MDedge Hematology and Oncology